2021 is on track to rival peak year 2018 in lobbying intensity on the 340B drug pricing program.
Attention on health care lobbying in Washington today focuses on the huge sums the drug industry is spending fighting Democratic drug price
…
Articles by : Tom Mirga, Editor at Large
Drug manufacturer Astra Zeneca and the federal government both want a federal district judge in Delaware to rule quickly in the drug company’s lawsuit over the government’s 340B contract pharmacy requirements.
The two sides, however, are miles apart on why
…
U.S. District Judge Dabney Friedrich of the District of Columbia has been assigned to a fourth 340B contract pharmacy lawsuit.
Boehringer Ingelheim’s (BI) lawsuit in defense of its policy of denying hospitals 340B drug discounts when hospitals use contract pharmacies
…
A federal court ruling on the legality and constitutionality of Arkansas’s 340B nondiscrimination law might not come until sometime in 2023.
U.S. Senior District Judge Billy Roy Wilson on Monday issued an initial scheduling order in the drug industry lawsuit
…
The U.S. Health Resources Services Administration (HRSA) has ordered two drug manufacturers that it audited—Akorn Inc. and BioComp Pharma—to repay 340B covered entities for overcharges.
HRSA updated its fiscal year 2021 audit results on its website last week.
The federal government and the two groups that sued it separately to force it to issue long delayed 340B administrative dispute resolution (ADR) regulations agreed last night to keep stays in place in both lawsuits until Jan. 3, 2022. Meanwhile,
…
A central Virginia community health center has joined an upstate New York health center’s antitrust lawsuit against four insulin and diabetes drug manufacturers over the companies’ denials of 340B pricing when covered entities use contract pharmacies.
Central Virginia Health Services’
…
Drug manufacturer Boehringer Ingelheim (BI) sued the federal government this afternoon in federal district court in Washington, D.C., in defense of its policy of denying hospitals 340B drug discounts when hospitals use contract pharmacies.
BI is the seventh manufacturer to
…
U.S. Senate appropriators say they’re happy with the federal government’s response to six drug manufacturers’ denials of 340B drug discounts involving contract pharmacy.
The Democratic-controlled Senate Appropriations Committee praised the U.S. Health Resources and Services Administration (HRSA) for its actions
…
The Biden administration yesterday formally announced that it wants to repeal a regulation issued during ex-President Trump’s last days in office that has helped to cast doubt on the authority of federal health care guidance, including for the 340B program.
…